GlaxoSmithKline has £1.6bn offer rejected
Drugs giant GlaxoSmithKline said it was disappointed that an offer worth £1.6bn (€1.94bn) for US-based Human Genome Sciences (HGS) has been rejected.
Despite an 81% premium to its Wednesday share price, HGS said the move undervalued its business.
The Business Hub
Newsletter
News and analysis on business, money and jobs from Munster and beyond by our expert team of business writers.





